ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...2829303132333435363738...129130»
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Using Twitter Data to Understand Public Perceptions of Approved versus Off-label Use for COVID-19-related Medications. (Pubmed Central) -  Jul 2, 2022   
    Our study found that social media users with have different perceptions and stances on off-label versus FDA-authorized drug use across different stages of COVID-19, indicating that health systems, regulatory agencies, and policymakers should design tailored strategies to monitor and reduce misinformation for promoting safe drug use. Our analysis pipeline and stance detection models are made public at https://github.com/ningkko/COVID-drug.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Drugs for sexually transmitted infections. (Pubmed Central) -  Jul 1, 2022   
    Our analysis pipeline and stance detection models are made public at https://github.com/ningkko/COVID-drug. No abstract available
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial completion date, Trial primary completion date:  A Phase III Confirmatory Study of K-237 (clinicaltrials.gov) -  Jul 1, 2022   
    P3,  N=1000, Recruiting, 
    No abstract available Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Ivermectin for preventing and treating COVID-19. (Pubmed Central) -  Jun 28, 2022   
    In this update, certainty of evidence increased through higher quality trials including more participants. According to this review's living approach, we will continually update our search.
  • ||||||||||  ivermectin oral / Generic mfg.
    Biomarker, Review, Journal:  Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19? (Pubmed Central) -  Jun 25, 2022   
    There are many types of available COVID-19 therapies, including antiviral agents (remdesivir, lopinavir/ritonavir, oseltamivir), antibiotics (azithromycin), antiparasitics (chloroquine, hydroxychloroquine, ivermectin), and corticosteroids (dexamethasone)...The knowledge of pharmacogenetic issues, which translate into variability in drug conversion from prodrug into drug, metabolism as well as transport, could help to predict treatment efficiency and the occurrence of adverse effects in patients. However, many drugs used for the treatment of COVID-19 have not undergone pharmacogenetic studies, perhaps as a result of the lack of time.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Transcription of the Envelope Protein by 1-L Protein-RNA Recognition Code Leads to Genes/Proteins That Are Relevant to the SARS-CoV-2 Life Cycle and Pathogenesis. (Pubmed Central) -  Jun 22, 2022   
    In the viral cycle, E supports the COPII-SCAP-SREBP-HSP90α transport complex by the lowering of cholesterol in the ER and by the repression of insulin signaling, which explains the positive effect of HSP90 inhibitors in COVID-19 (geldanamycin), and E also supports importin α/β-mediated transport to the nucleus, which explains the positive effect of ivermectin, a blocker of importins α/β. In summary, transcription of the envelope protein by the 1-L protein-RNA recognition code leads to genes/proteins that are relevant to the SARS-CoV-2 life cycle and pathogenesis.